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Influence of target hemoglobin in dialysis patients on morbidity have subsequently been tested in prospective clinical
and mortality. Since the introduction of recombinant human trials and observational studies to determine the impact
erythropoietin (rHuEPO) in 1989, the level of anemia correc- of anemia correction on mortality and the associatedtion has been debated. Information developed from clinical
morbidity.trials and observational studies have given conflicting results.
In the fall of 1997, the United States National KidneyThe normal hematocrit (Hct) trial of Besarab et al showed no
benefit, and a possible risk, of correcting the Hct from 30% Foundation published its Dialysis Outcomes Quality Ini-
to 42% in hemodialysis patients with NYHA class I to III tiative (DOQI) guidelines suggesting a target hemoglo-
cardiac disease. The study of Moreno et al in non-cardiac pa-
bin of 11–12 g/dL (Hct 33–36%) for dialysis patientstients showed improved Sickness Impact Profile and Karnofsky
based on a review of the literature and opinion of thescores in hemodialysis patients when their Hct was increased
from 31% to 38.5%. Hospitalizations were significantly re- anemia work group. The target level for correcting ane-
duced. Observational studies from Madore et al, Xia et al, Ma mia, which is below that of the normal population, has
et al, and Collins et al all show that increased morbidity and been suggested by some investigators to be lower than
mortality are significantly associated with Hct 33%. Recent
what should be achieved in order to reduce the highdata on incident hemodialysis patients indicate the associated
mortality in the dialysis population secondary to cardiacrisk of death was not different for patients with Hct 33 to
36% versus Hct 36 to39%. Hospitalization risks and associ- disease [11–13]. One study in the literature by Besarab
ated costs were significantly less in the patients with Hct 36 to et al has receive considerable attention because it tested
39%, suggesting that higher Hct values may be less of a the hypothesis that correcting hemodialysis patients’ he-concern than previously considered. The current data suggest
matocrits from 30% to 42% would reduce mortality andthat patents with advanced cardiac disease should avoid Hct
values in the normal range. In others, Hcts at least up to 39% morbidity in patients with cardiac disease. The study was
appear to be safe and effective. Based on this review, a reason- stopped early because the treatment group mortality was
able target Hct range may be 33 to 39%, which balances the not significantly higher than the control group, and that
risks and potential benefits.
there was little chance that the primary hypothesis of
an improved outcome would be achieved with the time
remaining in the trial. This study suggested that thereSince recombinant erythropoietin was introduced into
may be limits to the level of correction of anemia thatclinical practice in 1989 for the treatment of ESRD-
should safely be achieved in the dialysis population.related anemia, considerable attention has been spent
Given the countering views that a normal hematocriton determining the appropriate degree of correction of
(Hct) should be achieved and also the risks of completethe hemoglobin and the associated clinical benefits. A
correction of anemia, this article will review the trial datanumber of clinical trials have defined the physiologic
and observational studies to determine what evidence ischanges that occur when the hematocrit level is increased
available to address the safety of Hcts between 33% andfrom the pre-Epoetin era level of less than 30% to hema-
36%, and the 42% of a normal population level.tocrits of greater than 30%, and more recently, to hema-
tocrits in the higher ranges of 38–42% [1–5]. The clinical
benefits of correcting hematocrits to 30% have shown THE NORMAL HCT TRIAL IN PATIENTS WITH
improved exercise capacity, cognitive function, better CARDIAC DISEASE
quality of life, improved cardiac function, and improved
The evidence developed from earlier trials and thesexual function [6–10]. The physiologic improvements
observational studies suggested that patients with cardiac
disease, particularly those with left ventricular hypertro-
Key words: anemia, blood hematocrit, dialysis. phy and congestive heart failure, may benefit from a
higher Hct in the normal range. Subsequently, Besarab 2002 by the International Society of Nephrology
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et al in 1998 reported on a trial to test the hypothesis questioned as well, but no additional studies have been
reported to settle the debate [15–24].that mortality and morbidity would be reduced in pa-
tients with New York Heart Association classification
heart disease stage I–III when the Hct was increased to
HIGHER HEMATOCRIT LEVELS IN LOW RISK42% compared with a control group with the Hct sus-
POPULATIONS: IMPACT ON QUALITY OF LIFEtained at 30% [14]. Six hundred fifteen and six hundred
AND FUNCTIONAL STATUSeighteen prevalent hemodialysis patients were random-
Concerns over the lack of benefit of an increased Hctized to the treatment arms of 30% and 42%, respectively.
in patients with cardiac disease led a number of investiga-The higher Hct group required significantly more Epoe-
tors to reevaluate the clinical limits that can be achievedtin and intravenous iron to achieve the higher Hct levels.
in patients with established heart disease. Moreno et alThe primary outcome was time to death or first non-
studied patients without cardiac disease, accessing thefatal myocardial infarction. Secondary outcomes tracked
impact of increasing Hct levels over a six-month periodhospitalizations with detailed categorizations of the prin-
as reported in 2000 [25]. This multi-center prospectivecipal cause of the admissions. The follow-up period was
6 month interventional trial was performed in patients29 months, with the study terminated early secondary
with a mean Hct of 31%, increasing their Hct to 38.5%to a non-significant higher risk of death (RR  1.30; CI,
assessing their Sickness Impact Profile (SIP) and Karnof-0.09–1.90) in the Hct group 42%. This action will be
sky score before and after intervention. One hundredtaken since the remaining time in the study would not
fifteen patients without significant cardiac disease wereoffset the trends such that the principal hypothesis could
treated with their initial SIP of 8.9 and, after achievingnot be proven. Therefore, to reduce the potential risk
the higher Hct, the score decreased to 7.25 (P  0.001),to the study subjects, the trial was stopped. Less than
an 18.5% improvement. Their functional status also im-150 patients (12.1%) had been followed for 24 months
proved from a Karnofsky score initially of 75.6 to 78.4when the trial was stopped. Post hoc analysis showed
(P 0.01), a 3.7% improvement. Additional informationthat when the treated patients were divided by Hct level,
was presented on their pattern of morbidity from hospi-the normal Hct treatment group had higher death rates
talizations comparing the previous six months’ patterneven though their achieved Hcts were comparable to the
with that noted during the six-month intervention. Totallow Hct group. The higher death rate finding continued
hospitalizations were reduced 58% (P  0.05), and totalup to Hct levels of 36–39%; however, those patients that
hospital days decreased 69% (P  0.05). No patientachieved an Hct of 39–41% had a lower death rate. This
deaths were noted, and only 11 patients dropped out oflater observation may represent select and survivor bias
the study secondary to vascular access thrombosis (N and should be viewed with caution.
9, 5.7%) and hypertension (N  2, 2%). This study, inThe unexplained findings of a higher death rate in the
contrast with the Besarab et al study, showed a significantnormal Hct treatment arm raised concerns that the trial
improvement in both morbidity and patient well-being.may have had an unrecognized confounding element that
One possible explanation for these findings may centerwas not considered. The higher Hct treatment group
on the cohort studied. These low risk patients had lessresulted in significantly more the intravenous iron being
established disease that may have lowered the potentialgiven compared with the control group. The authors
risk as the higher Hct levels are achieved. The level ofsuggested that this confounding effect may contribute
anemia correction was also different in the Moreno etthe reasons for the differences in the outcomes. Unfortu-
nately, the post hoc nature of the analysis could not be al study, with patients achieving an average of 38.5%
compared with the Besarab et al study which targetedused to dismiss the trial findings that the normal Hct
group did not benefit with reduced mortality or a morbid- a 42% Hct. Another important comparison between the
two studies relates to the early deaths. In the Besarabity secondary to hospitalizations. The one area of clear
finding was related to an increase in vascular access et al normal Hct trial in patients with cardiac disease,
approximately 11% of the patients had died or had anthrombosis in the normal Hct group. These findings were
not subjected to the same Hct level analysis as was done acute myocardial infarct within the first six months of
the study. In contrast, the Moreno et al trial in patientsin the mortality report, thereby leaving the issue unre-
solved. Thus, this trial suggested that patients with car- without cardiac disease had no deaths during the six-
month treatment phase. The markedly different hospital-diac disease of NYHA class I–III do not benefit from a
Hct of 42% compared with an Hct of 30%. Unfortu- ization patterns between the studies at least suggest that
Hcts of 38.5% in non-cardiac disease patients are notnately, little else can be gleaned from this study as there
appears to be a concern about the use of large doses of only safe but also effective at reducing morbidity. This
was the first study to demonstrate improved outcomesIV iron, a suggested risk factor in the general population
for cardiac disease. This iron hypothesis has also been in patients with an Hct above the DOQI target of 36%.
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OBSERVATIONAL STUDIES DEMONSTRATING ables included age, gender, co-morbidity, dialysis mod-
ality, and prior ESRD time. The outcome was the oddsAN ASSOCIATION BETWEEN HCT LEVELS
ratio of death in the next year of followup assessed in aAND CLINICAL OUTCOMES
logistic regression model. Also, the hospitalization ratesIn contrast to the above randomized prospective con-
and total hospital days were evaluated between the threetrolled multi-center trial and the prospective interven-
Hct ranges. Crude mortality was highest at 16% in thetional study, at least five observational studies have been
Hct group of 27% and was lower at 11% in the Hctpublished showing a lower associated morbidity and
group of32%. Cardiovascular death and cerebrovascu-mortality when the Hct level was greater than 30% [8,
lar death were also lowest in the group of32%. Hospi-9, 26–28]. The first study demonstrating this association
talization days were the lowest on the Hct group ofwas published in 1997 by Madore et al. This observa-
32% at 11 days compared with 13 days for the grouptional study investigated 18,792 patients who were alive
of 27–32% and 16.5 days per patient’s year at risk. Thisat the end of 1992, with three months of biochemical
study established the lower associated hospitalizationand Hct data available from October, November, and
risk when the patients Hct was 32% compared withDecember 1992, with followup through 1993. Because
lower levels of anemia correction. The findings of lowerobservational studies must address potential selection
cerebral vascular deaths also allayed concerns about thebias, the investigator added increasing amounts of clini-
potential risk of hypertension and cerebral vascularcal data to the logistic regression model odds ratio of
events when patients’ Hcts were corrected to levelsdeath. Three models were run with age, gender, and race
above 30% [27].only, the previous model with albumin and the final
Two large national studies from the United Statesmodel which added monthly biochemical data and urea
were subsequently published by Ma et al and Xia et alreduction ratio. Each of the models gave very similar
in 1999 which were companion studies on the same co-results, with the highest odds of death occurring in the
hort of Medicare hemodialysis patients from 1993. Thesepatients with hemoglobins of80 g/L (OD: 1.5–2.0) com-
authors first reported mortality associations with the sec-
pared with those with hemoglobins of 100–110 g/L. The
ond paper addressing the risk of hospitalization. These
risk decreased to 25% higher at hemoglobins of 90–100 investigators evaluated prevalent Medicare hemodialysis
g/L and were not significantly different for those hemo- patients that survived the period from July 1, 1993 to
globins of greater than 110 g/L. The additional case mix December 31, 1993, assessing their co-morbidity, history
and clinical data adjustment only changed the associated of vascular access procedures, history of blood transfu-
risks in the groups with hemoglobins of less than 90 g/L sions, and total hospital days during the six-month entry
with the others being unchanged [26]. period. The severity of disease measures were deter-
This study supported the hemoglobin range of 100–110 mined to address the concerns that patients with lower
g/L but did not demonstrate any benefit associated with Hcts may have a greater degree of co-morbidity that
the higher hemoglobin levels above 110 g/L. One concern could confound analysis. Hcts were computed for pa-
about this study was the analysis of the patients with tients who had at least 3 measurements in the six-month
hemoglobins above 110 g/L. The payment policies in the entry period to better characterize the stability of the
United States were restrictive for patients with hemoglo- Hct level and whose measurements would be representa-
bins above 120 g/L such that those patients needed medi- tive of the six-month fixed survival period. All patients
cal indications to justify Epoetin treatment to sustain a were followed for one year assessing the risk of death
higher hemoglobin level. Therefore, not all patients were in a Cox regression model and the risk of multiple hospi-
able to achieve this level of hemoglobin correction in talizations using an Anderson-Gill multiple event model.
addition to the fact that the higher hemoglobin group Sensitivity analyses were performed for both studies to
may have had more disease. To the extent that the adjust- determine how many patients would be required in each
ment could address these differences, there was no bene- Hct group in order to achieve a significant result in the
fit from a mortality standpoint between the group with higher Hct groups [8, 9].
a hemoglobin level of 100–110 g/L and those greater The risk of first and multiple hospitalizations followed
than 110 g/L. This study did clearly establish that patients the mortality pattern previously reported by Madore et
with lower hemoglobins were associated with significant al and Locatelli et al but differed in that patients with
adverse outcomes. Hcts of 33–36% had a 8% significantly lower risk than
Supporting evidence for the above observational study patients with Hcts of 30–33%. The sensitivity analysis
was subsequently reported by Locatelli et al in 1998 in showed that the higher Hct level results associated with
a report from the Lombardy dialysis registry in northern hospitalizations required at least 3500 to 4000 patients
Italy. In this study, 5,302 prevalent dialysis patients alive in the Hct group of 33–36% in order to determine the
on December 31, 1995 were characterized into Hct significance of risk. The mortality associations by Ma et
al were similar to the Madore et al and Locatelli et algroups of27%, 27–32%, and32%. Explanatory vari-
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morality studies but showed a 4% lower risk of death may be secondary to selection bias in that patients with
less co-morbidity and severity of disease may be moreat an Hct of 33–36% compared with the Hct group of
30–33%. The sensitivity analysis showed that the mortal- responsive to Epoetin and therefore will require lower
doses. The study attempted to adjust for these differ-ity findings in the higher Hct group required at least
16,000 patients in that cell in order to achieve signifi- ences; however, these findings should be viewed only as
associations and not causal. A more definitive studycance. The low sensitivity of the mortality event is consis-
tent with all the previous trials including the Besarab et would require a prospective randomized design to dem-
onstrate the direct relationship.al study which was a randomized trail of 600 patients
in each cell (Hct 30% vs. 42%) which would have been The latest study on incident patients demonstrating
an association between a lower risk of hospitalization inunderpowered to show any impact of the higher Hct
level in either the mortality event or the hospitalization patients with Hcts of 36–39% and no adverse mortality
risk compared with patients with Hcts of 33–36% sug-event. Therefore, conclusions about the impact of higher
Hcts are vulnerable to the size of the reported study. gests that the concerns raised by the normal Hct trial
In November 2001 Collins et al published a study of may be important to reconsider. The clinical reality is
incident Medicare hemodialysis patients from 1996 that the dialysis population appears to initiate ESRD
through June 30, 1998. Each patient survived to month treatment with an Hct on average of 30% and increase
9 after the ESRD first service date, and their Hct levels their Hct over a three or four month period toward an
were determined in the month 4 to month 9 period of Hct at the midpoint of the DOQI range [29]. Few data
survival. The patients were characterized for co-morbid- are available in this early correction phase that mimics
ity, severity of disease, and Hct levels in a manner that the ramp-up phase of the normal Hct trial which showed
was previously used in the Ma et al and Xia et al studies. an increased risk of death in patients with severe cardiac
Followup of the patients was for one year with the out- disease. More investigation is needed to determine if the
come being the risk of death or first hospitalization. A higher Hct levels pose an early risk of death to patients.
Cox regression model was used with adjustments for age, The observational data and the study by Marone et al
gender, race, diabetes, co-morbidity, severity of disease, would suggest that Hcts of 36–39% may be effective in
and Hct level. The analysis also evaluated the relative the hemodialysis population compared with the 33–36%
cost of Medicare allowable expenditures based on the Hct current target. From this standpoint, it may be clinically
levels. The findings in this incident population were more reasonable to broaden the target range to 33–39%, which
definitive than the 1993 prevalent cohort in that the asso- would be a more reasonable biologic range based on the
ciated risk of death was lowest in the Hct group of 33– variability in a patient’s Hct level month to month. It is
36% and was not different in the Hct group of 36–39% still prudent to limit the increase in Hcts in Epoetin-
or the 39% groups. Based on the previous sensitivity treated patients with cardiac disease to below 42% until
studies from these authors, the mortality analysis was more definitive studies are performed.
underpowered to demonstrate any impact on mortality.
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